Why is Emcure Pharma falling/rising?

As of 04-Jul, Emcure Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 1,253.75, which represents a decrease of Rs 27.4 or 2.14%. The stock has underperformed its sector by 2.65% today, touching an intraday low of Rs 1,247.65. Over the past week, the stock has decreased by 3.19%, and it has seen a significant drop of 12.81% year-to-date, contrasting with the Sensex's gain of 6.77% during the same period. Despite the company demonstrating high management efficiency with a return on capital employed (ROCE) of 20.07% and a strong ability to service debt, the stock's performance is hindered by poor long-term growth prospects, with operating profit growing at an annual rate of only 8.80% over the last five years.
In the broader market context, Emcure's short-term performance has been notably weaker compared to the Sensex, which has gained 3.01% over the past month while Emcure has declined by 5.84%. This underperformance is compounded by the stock's expensive valuation, indicated by a high enterprise value to capital employed ratio of 4.7. Although the company has reported positive results for the last three consecutive quarters, the stock has generated no returns over the past year, despite a 36% increase in profits. This combination of factors contributes to the stock's current downward trend in a market that is otherwise showing positive momentum.